MSN Deals Out Of Movantik But Two ANDA Filers Remain

Indian Firm Bags Date-Certain Launch

 
• By Dean Rudge

India’s MSN Laboratories is set to move on a generic version of RedHill Biopharma’s Movantik (naloxegol oxalate) for opioid-induced constipation ahead of patent expiry under the terms of a patent-litigation settlement agreement.

Gavels
MSN has settled litigation with a number of plaintiffs with interest in the Movantik brand. • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin